Click on headlines below to download research

Tuzistra XR downgrade prompts strategic rethink
Vernalis | 28/02/2018

Vernalis has provided a trading and operational update to its guidance for Tuzistra XR prescriptions for financial year-end 2018. Despite dynamic management…

Operational initiatives in place, execution is key
Vernalis | 22/11/2017

Tuzistra XR prescriptions (Rx) grew threefold to ~35k in FY16/17 (2nd year on the market) vs ~12k in FY15/16. Investment into addressing the barriers to…

Tuzistra XR steady growth in Rx run rate
Vernalis | 19/07/2017

Vernalis has provided a year-end trading and operational update ahead of its FY17 results due to be announced on 12 September. Total revenues are expected…